OncoMed and Celgene to jointly develop six cancer drugs

(Reuters) - OncoMed Pharmaceuticals Inc said Celgene Corp would develop and market six of its anti-cancer stem cell experimental drugs for an upfront payment of $155 million. OncoMed's stock rose 68 percent to $23.50 in premarket trading on Tuesday. OncoMed is eligible to receive up to $3 billion in option and milestone payments if Celgene's option to license worldwide rights is exercised and approved, the companies said in a statement. Celgene will also buy about $22.25 million of OncoMed's common stock for $15.13 per share, an 8 percent premium to OncoMed's closing on Monday. via Health News Headlines - Yahoo! News Read More Here..

For a Free Step By Step Guide for Dating Dos and Don'ts check http://end2endwebs.com

Lake forest health and fitness http://healthandfitness1blog.blogspot.com/2013/12/oncomed-and-celgene-to-jointly-develop.html